Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Safety and Efficacy of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Cells after Myeloablative Conditioning

wagner, John and brunstein, claudio and Boitano, Anthony and DeFor, Todd and McKenna, David and Sumstad, Darin and Blazar, Bruce and Tolar, Jakub and Le, Chap and Jones, Julie and Cooke, Michael and Bleul, Conrad (2015) Safety and Efficacy of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Cells after Myeloablative Conditioning. Cell Stem Cell.

Abstract

Umbilical cord blood (UCB) transplantation is limited by low CD34+ cell dose, increased risk of graft failure and slow hematopoietic recovery. Therefore, we evaluated the feasibility, safety and potential efficacy of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist, previously shown to enable marked expansion of human CD34+ cells. In a first-in-human clinical trial, SR-1 resulted in a 330-fold (68-609) increase in CD34+ cells and led to engraftment in 17/17 patients at a median of 15 (6-30) days for neutrophils and 49 days (28-136) for platelets. Furthermore, a comparison to 111 control patients treated with an identical conditioning regimen and immunoprophylaxis followed by transplantation of unmanipulated UCB demonstrated significantly faster neutrophil and platelet recovery (p<0.001 and p=0.001, respectively) in recipients of SR-1 expanded UCB. Marked expansion, absence of graft failure and enhanced hematopoietic recovery together suggest that SR-1 may well have ameliorated one of the principal obstacles of UCB transplantation.

Item Type: Article
Date Deposited: 31 May 2016 23:45
Last Modified: 31 May 2016 23:45
URI: https://oak.novartis.com/id/eprint/26403

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.